| Code | CSB-RA023981MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to BAT-6026, designed to target TNFRSF4 (Tumor Necrosis Factor Receptor Superfamily Member 4), also known as OX40 or CD134. TNFRSF4 is a costimulatory receptor primarily expressed on activated T cells that plays a crucial role in T cell activation, proliferation, and survival. Upon binding with its ligand OX40L, this receptor enhances immune responses by promoting effector and memory T cell development while modulating regulatory T cell function. TNFRSF4 has emerged as a significant target in immuno-oncology research and autoimmune disease studies, as its modulation can enhance anti-tumor immunity or regulate excessive inflammatory responses.
BAT-4706 is a biosimilar drug developed based on the original reference drug, ipilimumab, a classic immunotherapy drug. As an antagonist of CTLA-4, it blocks the binding of CTLA-4 to its ligand, thereby relieving the inhibition on T cells and activating the immune system to attack tumor cells. This biosimilar antibody serves as a valuable research tool for investigating TNFRSF4-mediated signaling pathways, studying T cell biology, and exploring therapeutic strategies in oncology and immunology research. It enables researchers to conduct mechanistic studies and preclinical evaluations of OX40-targeted immunomodulation.
There are currently no reviews for this product.